12th Congress of the Polish Transplantation Society
Organ procurement
A Cell Graft or a Drug? Legal and Practical Aspects of Somatic Cells Application in Graft-Versus-Host Disease Experimental Treatment: The Polish Experience

https://doi.org/10.1016/j.transproceed.2016.03.027Get rights and content

Highlights

  • Steroid-refractory GvHD is a field of growing interest for experimental cell therapies with mesenchymal stem/stromal cells as well as regulatory T cells.

  • According to current law in European Union, human cells intended for human application can be consider either as cell grafts or as advanced therapy medicinal products (ATMP).

  • There are 3 main kinds of ATMP: gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineering medicinal products.

  • Cells that are expanded in vitro become an ATMP.

  • ATMP, which is prepared on a nonroutine basis according to specific quality standards and used within the same Member State in a hospital under the exclusive professional responsibility of a medical practitioner to comply with an individual medical prescription for a custom-made product for an individual patient, is excluded from the scope of the EU Pharmaceutical Directive.

Abstract

Introduction

Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation and organ transplantation are well-established treatments for different conditions. Graft versus host disease (GvHD) is a major complication in both methods. There has been a rapid increase in the application of nonhematopoietic somatic cells, such as mesenchymal stem cells and regulatory T cells in GvHD experimental therapy. According to current European Union (EU) law, human cells intended for human application can be considered either as cell grafts or as advanced therapy medicinal products (ATMPs).

Objective, Materials and Methods

The aim of the paper is an attempt to answer, based on GvHD experimental treatment data as well as existing EU and Polish law, whether cells cease to be cells (cell grafts) and becomes drugs (ATMPs); if yes, when; and what are the consequences of such situation both for patients as well as for physicians engaged in the treatment process in Poland.

Results and Discussion

Data analysis confirmed the interest in the experimental GvHD cell therapy. In the vast majority of analyzed cases the in vitro culture step in the cell preparation protocols has been foreseen. Therefore, the answer to title question was unambiguous—expanded cells are recognized in EU as ATMPs. In borderline cases, a scientific recommendation by the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) can play an important auxiliary role; however, it is currently neither required by Polish law nor legally binding in Poland.

Section snippets

Mesenchymal Stem/Stromal Cells

MSCs are defined as self-renewing, multipotent progenitor cells with multilineage potential. In 2006, the minimal criteria for definition of MSCs were published by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy [5]. MSCs have been shown to possess an enormous number of immunomodulatory properties in vitro and in vivo, regulating both adaptive and innate immune responses [3]. Therefore, in the last decade a large number of clinical studies were

Summary

Attempts to treat seriously ill patients, including patients with steroid-refractory GvHD, by MSC or Treg application have been undertaken in Poland [24], [25]. The exact number of cases is not known—there is no legal obligation to provide official statistics. However, taking into account the lack of registered clinical trials in Poland e.g. in the field of GvHD treatment, it can be assumed that administrated cells were in the majority of cases HE-ATMPs by law. It means that everything that was

References (25)

  • R. Herrmann et al.

    Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

    Int J Hematol

    (2012)
  • M.M. Lalu et al.

    Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials

    PLoS One

    (2012)
  • Cited by (0)

    View full text